Revvity Inc. (RVTY) To Go Ex-Dividend on January 16th

Revvity Inc. (NYSE:RVTY) announced a quarterly dividend on Thursday, October 23rd. Investors of record on Friday, January 16th will be given a dividend of 0.07 per share on Friday, February 6th. This represents a c) dividend on an annualized basis and a yield of 0.3%. The ex-dividend date of this dividend is Friday, January 16th.

Revvity has a payout ratio of 5.1% meaning its dividend is sufficiently covered by earnings. Analysts expect Revvity to earn $5.56 per share next year, which means the company should continue to be able to cover its $0.28 annual dividend with an expected future payout ratio of 5.0%.

Revvity Stock Up 1.4%

RVTY opened at $98.91 on Friday. The firm has a 50 day moving average price of $89.38 and a 200 day moving average price of $92.42. The company has a market cap of $11.48 billion, a PE ratio of 41.91, a price-to-earnings-growth ratio of 3.25 and a beta of 0.98. Revvity has a 1 year low of $81.36 and a 1 year high of $129.50. The company has a debt-to-equity ratio of 0.43, a quick ratio of 2.75 and a current ratio of 3.33.

Revvity (NYSE:RVTY) last posted its earnings results on Monday, July 28th. The company reported $1.18 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.14 by $0.04. The firm had revenue of $720.28 million during the quarter, compared to the consensus estimate of $711.26 million. Revvity had a net margin of 10.19% and a return on equity of 7.66%. The company’s revenue was up 4.1% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.22 EPS. Revvity has set its FY 2025 guidance at 4.850-4.950 EPS. Sell-side analysts expect that Revvity will post 4.94 earnings per share for the current year.

About Revvity

Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.